Dementia affects approximately 55 million people worldwide, with its prevalence steadily increasing as global populations age ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

While dementia is much more common in older adults, hundreds of thousands of people are diagnosed with young-onset dementia ...

Experts say there are ways to reduce our risk of dementia, including diet and exercise, protecting against hearing loss, and ...

Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of ...

“Sundowning is not a type of dementia but a phenomenon that happens to many individuals with dementia later in the day,” explains Adria Thompson, CCC-SLP, a certified dementia practitioner and founder ...

The number of people diagnosed with dementia is skyrocketing worldwide. But treating even common health issues like high ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce ...